Company Snapshot: Retrophin, Inc.
Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, New York-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin has begun enrollment in a potentially pivotal Phase 2 clinical trial of its lead compound, sparsentan, for FSGS. The Company also intends to reintroduce Syntocinon Nasal Spray (oxytocin) in the U.S. to assist initial postpartum milk ejection and also initiate clinical trials for the drug as a potential treatment for schizophrenia and autism. Retrophin plans to initiate a Phase 1 pharmacokinetic trial of RE-034, an ACTH analog, in the first half of 2014.
- Jan 7 2019 Retrophin Provides Corporate Update and 2019 Outlook
- Jan 3 2019 Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer
- Jan 2 2019 Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
- Dec 27 2018 Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy